Evidence map›Paper›PMID 19110040›Full record

ArticleNeuroscience2009

Signaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord.

H-M Zhang, S-R Chen, Y-Q Cai, T E Richardson, L C Driver, G Lopez-Berestein, H-L Pan

Open access · greenAbstract read
In one paragraph

Article in Neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.Methods in molecular biology (Clifton, N.J.) · 2016
    Article
  5. Article
  6. Review
  7. Article
  8. Targeted gene silencing using RGD-labeled chitosan nanoparticles.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

H-M ZhangDepartment of Anesthesiology and Pain Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
S-R Chen
Y-Q Cai
T E Richardson
L C Driver
G Lopez-Berestein
H-L Pan
The University of Texas MD Anderson Cancer Center · US

Funding

Mechanisms of Neural Plasticity in Neuropathic PainR01GM064830 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PAN, HUI-LIN · 2001 to 2010
$2.0M
Spinal Plasticity In Diabetic Neuropathic PainR01NS045602 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PAN, HUI-LIN · 2003 to 2010
$1.9M
NIGMS NIH HHS GM64830NIGMS NIH HHS R01 GM064830NINDS NIH HHS NS45602NINDS NIH HHS R01 NS045602
6 · The paper itself

Abstract

Activation of muscarinic acetylcholine receptors (mAChRs) inhibits spinal nociceptive transmission by potentiation of GABAergic tone through M(2), M(3), and M(4) subtypes. To study the signaling mechanisms involved in this unique mAChR action, GABAergic spontaneous inhibitory postsynaptic currents (sIPSCs) of lamina II neurons were recorded using whole-cell patch clamp techniques in rat spinal cord slices. The mAChR agonist oxotremorine-M caused a profound increase in the frequency of GABAergic sIPSCs, which was abolished in the Ca(2+)-free solution. Inhibition of voltage-gated Ca(2+) channels with Cd(2+) and Ni(2+) largely reduced the effect of oxotremorine-M on sIPSCs. Blocking nonselective cation channels (NSCCs) with SKF96365 or 2-APB also largely attenuated the effect of oxotremorine-M. However, the KCNQ channel blocker XE991 and the adenylyl cyclase inhibitor MDL12330A had no significant effect on oxotremorine-M-induced increases in sIPSCs. Furthermore, the phosphoinositide-3-kinase (PI3K) inhibitor wortmannin or LY294002 significantly reduced the potentiating effect of oxotremorine-M on sIPSCs. In the spinal cord in which the M(3) subtype was specifically knocked down by intrathecal small interfering RNA (siRNA) treatment, SKF96365 and wortmannin still significantly attenuated the effect of oxotremorine-M. In contrast, SKF96365 and wortmannin both failed to alter the effect of oxotremorine-M on sIPSCs when the M(2)/M(4) mAChRs were blocked. Therefore, our study provides new evidence that activation of mAChRs increases synaptic GABA release through Ca(2+) influx and voltage-gated Ca(2+) channels. The PI3K-NSCC signaling cascade is primarily involved in the excitation of GABAergic interneurons by the M(2)/M(4) mAChRs in the spinal dorsal horn.

Indexed as

AnimalsAnthracenesBiophysicsCadmiumCalciumDrug InteractionsElectric StimulationEnzyme Inhibitorsgamma-Aminobutyric AcidGene Expression RegulationInhibitory Postsynaptic PotentialsIn Vitro TechniquesIon Channel GatingMaleMuscarinic AgonistsNeural Inhibition10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenoneAnthracenesCadmiumCalciumEnzyme Inhibitorsgamma-Aminobutyric AcidMuscarinic AgonistsNickelOxotremorineoxotremorine MPotassium Channel BlockersReceptors, MuscarinicRNA, MessengerRNA, Small Interfering

Identifiers

PMID19110040
PMCPMC2646800
OpenAlexW1965723062

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.